Cerezyme® (imiglucerase) for injection logo

Cerezyme® (imiglucerase) Dosing and Administration


Cerezyme dosing can be individualized for each patient1

Recommended Cerezyme dosing and administration

Cerezyme is administered as an intravenous infusion1

  • The recommended dosage of Cerezyme based upon disease severity ranges from 2.5 units/kg 3 times a week to 60 units/kg once every 2 weeks
  • For patients weighing 18 kg and greater, infuse the diluted Cerezyme solution over 1 to 2 hours. For patients weighing less than 18 kg, infuse the diluted Cerezyme solution over 2 hours
  • Titrate the dosage based on clinical manifestations of disease and therapeutic goals for the patient
  • Initiate Cerezyme in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment
  • If a severe hypersensitivity reaction occurs, discontinue Cerezyme treatment and initiate appropriate medical treatment
  • For patients who experience a hypersensitivity reaction to Cerezyme and a decision is made to readminister the product, consider reducing the rate of infusion and pretreat with antihistamines and/or corticosteroids. Monitor patients for the occurrence of new hypersensitivity reactions

How to prepare and administer Cerezyme1

Reconstitute each 400-unit vial of Cerezyme by slowly injecting 10.2 mL of Sterile Water for Injection, USP, down the inside wall of each vial

Roll and tilt the vial to allow the powder to dissolve completely. Each vial will yield a concentration of Cerezyme after reconstitution of 40 units/mL. Visually inspect the solution after reconstitution for particulate matter and discoloration. Discard if opaque particles or discoloration are observed

Withdraw up to 10 mL per vial. Discard unused portion

Dilute the Cerezyme solution promptly with 0.9% Sodium Chloride Injection, USP, to a final volume of 100 to 200 mL

For patients weighing less than 18 kg, dilute Cerezyme to a final volume of 100 mL. Gently invert infusion bag to mix the solution, avoiding vigorous shaking and agitation. Visually inspect the solution prior to administration of the final product for particulate matter and discoloration. Slight flocculation of protein particles (described as thin translucent fibers) may occur after dilution and does not affect the quality of the product

The diluted solution may be filtered through an in-line low protein-binding 0.2 μm filter during administration

If the reconstituted Cerezyme vial is not used immediately, store at room temperature at 68 °F to 77 °F (20 °C to 25 °C) or refrigerated at 36 °F to 46 °F (2 °C to 8 °C) for up to 12 hours

After dilution, Cerezyme is stable for up to 24 hours when stored refrigerated at 36 °F to 46 °F (2 °C to 8 °C)

Download the Cerezyme Reconstitution & Administration Guide for detailed guidance on preparation and administration.

Storing Cerezyme1

  • Cerezyme does not contain preservatives
  • Cerezyme for injection is supplied as a white to off-white lyophilized powder in a single-dose vial: NDC 58468‑4663‑1
  • Cerezyme vials should be stored refrigerated at 2 °C to 8 °C (36 °F to 46 °F)

An established ERT for children ages 2 and up

Studied in the largest reported group of pediatric patients with Gaucher disease type 1

Gaucher disease type 1 is manageable once diagnosed

When an ERT is needed, choose the longest-approved therapy

Indication

Indication and Usage:

Cerezyme® (imiglucerase) for injection is indicated for treatment of adults and pediatric patients 2 years of age and older with Type 1 Gaucher disease that results in one or more of the following conditions:

  • anemia
  • thrombocytopenia
  • bone disease
  • hepatomegaly or splenomegaly

Important Safety Information

WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS

Patients treated with enzyme replacement therapies have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy.

Initiate CEREZYME in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue CEREZYME and immediately initiate appropriate medical treatment, including use of epinephrine. Inform patients of the symptoms of life-threatening hypersensitivity reactions, including anaphylaxis, and to seek immediate medical care should symptoms occur.

Warnings and Precautions:

Hypersensitivity Reactions Including Anaphylaxis: See Boxed WARNING.
Patients with antibody to imiglucerase have a higher risk of hypersensitivity reactions. Consider periodic monitoring during the first year of treatment for lgG antibody formation.

Consider risks and benefits of readministering Cerezyme to individual patients following a severe reaction. Consider reducing the rate of infusion, pretreat with antihistamines and/or corticosteroids, and monitor patients for new signs and symptoms of a severe hypersensitivity reaction.

Infusion-Associated Reactions:
Infusion associated reactions (IARs) have been observed in patients treated with Cerezyme. If an IAR occurs, decreasing the infusion rate, temporarily stopping the infusion and/or administering antihistamines and/or antipyretics may ameliorate the symptoms. Closely monitor patients who have experienced IARs when re-administering Cerezyme.

Adverse Reactions:
Adverse reactions reported in adults include back pain, chills, dizziness, fatigue, headache, hypersensitivity reactions, nausea, pyrexia, and vomiting.

Adverse reactions reported in pediatric patients 2 years of age and older are similar to adults.

Please see full Prescribing Information, including Boxed WARNING.

Indication

Important Safety Information

Reference: 1. Cerezyme (imiglucerase). Prescribing information. Genzyme Corporation, Cambridge, MA.

© 2025 Sanofi. All rights reserved. Cerezyme and Sanofi are registered trademarks of Sanofi or an affiliate. MAT-US-2015543-v3.0-08/2025